<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>260119</rcn>
  <id>101144681</id>
  <acronym>MYCureX</acronym>
  <teaser>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with very few and often ineffective therapeutic options. Despite recent advances, cancer therapies remain ineffective and/or highly toxic. Our approach is targeting MYC, a function essential to cancer...</teaser>
  <objective>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with very few and often ineffective therapeutic options. Despite recent advances, cancer therapies remain ineffective and/or highly toxic. Our approach is targeting MYC, a function essential to cancer cells that allows them to survive and develop resistance to therapy. In contrast to standard drugs, inhibiting MYC selectively blocks tumor progression without causing important side effects. MYC has been considered undruggable for a long time, and no clinical MYC inhibitor is yet marketed. Peptomycs first-in-class drug, OMO-103, is a cell-penetrating mini-protein that derives from Omomyc, the best MYC inhibitor known to date. OMO-103 recently completed a Phase 1 clinical trial that confirmed its safety and clinical activity in all-comers solid tumor patients, causing a 49% tumor shrinkage in a PDAC patient and stabilizing the disease of 8 out of 12 evaluable patients. Moreover, using AI we identified a predictive and a pharmacodynamic circulating biomarker signatures, and generated companion diagnostic for stratification and real-time response monitoring tests for OMO-103. OMO-103 and its companion diagnostic tests offer a promising therapeutic option for a disease in great need and could apply to treat many other cancer indications. The next steps and goals of this MYCureX project consist of conducting a Phase 1b trial in 1st-line PDAC patients, combining OMO-103 with the standard of care, to evaluate its safety and clinical activity; refining the companion diagnostic prototypes and app; securing the scale-up of the innovation by developing a commercial-scale compatible manufacturing process; and expand the applications of OMO-103 and Peptomyc's drug pipeline. By completing MYCureX, Peptomyc will consolidate the therapeutic potential of MYC inhibition in cancer patients, improving their survival and quality of life while establishing itself as a European leader biotech in MYC targeting.</objective>
  <title>FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY</title>
  <totalCost>3563578.25</totalCost>
  <ecMaxContribution>2494504</ecMaxContribution>
  <startDate>2023-07-01</startDate>
  <endDate>2025-12-31</endDate>
  <ecSignatureDate>2024-02-08</ecSignatureDate>
  <duration>30</duration>
  <status>SIGNED</status>
  <keywords>MYC, Undruggable target, Cell-penetrating mini-protein drug, First-in-class, First-in-modality, Companion diagnostic, Machine learning-enabled biomarkers discovery, Omics</keywords>
  <identifiers>
    <grantDoi>10.3030/101144681</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2024-12-31 09:30:22</sourceUpdateDate>
  <contentCreationDate>2024-02-13 18:46:08</contentCreationDate>
  <contentUpdateDate>2025-09-01 23:33:11</contentUpdateDate>
  <lastUpdateDate>2025-09-19 14:48:42</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>449795</rcn>
        <id>449795-inhibition-of-myc-in-pancreatic-cancer</id>
        <title>Inhibition of MYC in pancreatic cancer</title>
        <contentUpdateDate>2024-06-06 16:54:00</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55873</rcn>
        <title>HORIZON-EIC-2023-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2023-ACCELERATOR-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55873</rcn>
        <title>HORIZON-EIC-2023-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2023-ACCELERATOR-01</identifier>
      </call>
      <organization netEcContribution="2494504" totalCost="3563578.25" source="corda" order="1" ecContribution="2494504" terminated="false" sme="true" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>2384571</rcn>
        <id>934454545</id>
        <vatNumber>ESB66430653</vatNumber>
        <legalName>PEPTOMYC SL</legalName>
        <shortName>PEPTOMYC SL</shortName>
        <address>
          <street>CENTER CELLEX, CALLE NATZARET 115-117</street>
          <city>BARCELONA</city>
          <postalCode>08035</postalCode>
          <country>ES</country>
          <geolocation>41.370449300000004,2.1500219563810696</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Spain</name>
              <rcn>242387496</rcn>
              <nutsCode>ES</nutsCode>
              <euCode>ES</euCode>
              <isoCode>ES</isoCode>
            </region>
            <region type="relatedRegion">
              <name>Spain</name>
              <rcn>242387496</rcn>
              <nutsCode>ES</nutsCode>
              <euCode>ES</euCode>
              <isoCode>ES</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>707276</rcn>
        <id>HORIZON_HORIZON-EIC-2023-ACCELERATOROPEN-01</id>
        <code>HORIZON-EIC-2023-ACCELERATOROPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Accelerator Open 2023</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1124929</rcn>
        <id>101144681_PSHORIZON</id>
        <title>Periodic Reporting for period 2 - MYCureX (FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY)</title>
        <description>periodic</description>
        <teaser>Cancers are a leading cause of mortality, accounting for nearly 10 million (M) annual deaths worldwide. Personalized medicine and immunotherapy have improved the prognosis for several patients, yet their applicability remains limited, often targeting redundant cell functions...</teaser>
        <sourceUpdateDate>2025-06-11 22:15:29</sourceUpdateDate>
        <contentUpdateDate>2025-06-11 22:15:29</contentUpdateDate>
        <relations>
          <associations>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/figure-3.png</uri>
              <alternativeText>Peptomyc published the results of the OMO-103 FIH trial in Nature Medicine</alternativeText>
              <mimetype>image/png</mimetype>
              <size>366592</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/figure-4.png</uri>
              <alternativeText>Peptomyc presented the company’s project at Bio-Europe Spring 2024</alternativeText>
              <mimetype>image/png</mimetype>
              <size>526336</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/myc-kras.png</uri>
              <alternativeText>Publication of a review article on the cooperation between MYC and RAS in cancer</alternativeText>
              <mimetype>image/png</mimetype>
              <size>169984</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/osteosarcoma.png</uri>
              <alternativeText>Peptomyc announces the beginning of an investigator-led Phase II trial in osteosarcoma</alternativeText>
              <mimetype>image/png</mimetype>
              <size>45056</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/figure-5.png</uri>
              <alternativeText>Peptomyc was awarded as the most innovative company of the year by El Periódico</alternativeText>
              <mimetype>image/png</mimetype>
              <size>1423360</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/myc-cancer.png</uri>
              <alternativeText>Publication of a review article about the journey of targeting MYC in Nature Reviews Drug Discovery</alternativeText>
              <mimetype>image/png</mimetype>
              <size>167936</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/patent.png</uri>
              <alternativeText>Peptomyc announces the expansion of its patent portfolio</alternativeText>
              <mimetype>image/png</mimetype>
              <size>62464</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/indapproval.png</uri>
              <alternativeText>Peptomyc announces IND approval to conduct a WoO trial in the U.S. in PDAC patients.</alternativeText>
              <mimetype>image/png</mimetype>
              <size>119808</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/figure-2.png</uri>
              <alternativeText>Peptomyc announces first patient dosed in Phase Ib trial</alternativeText>
              <mimetype>image/png</mimetype>
              <size>153600</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/premis.png</uri>
              <alternativeText>Laura Soucek, CEO of Peptomyc, receiving the Premi Ciutat de Barcelona</alternativeText>
              <mimetype>image/png</mimetype>
              <size>251904</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/sandiego.png</uri>
              <alternativeText>Peptomyc representing its research and innovation at BIO International Convention in San Diego</alternativeText>
              <mimetype>image/png</mimetype>
              <size>227328</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/figure-1.png</uri>
              <alternativeText>Peptomyc announces the approval of its phase 1b trial</alternativeText>
              <mimetype>image/png</mimetype>
              <size>151552</size>
            </webItem>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1237574</rcn>
        <id>101144681_CFA069B7D8A12C2D44DD37B792D3BC4C_IPRHORIZON</id>
        <title>Compound for the treatment of autoimmune diseases</title>
        <details>
          <iprAwarded></iprAwarded>
          <iprNumber>EP24382257.4</iprNumber>
          <iprDate>2024-03-11</iprDate>
          <iprPrefix>EP24382257.4</iprPrefix>
        </details>
        <sourceUpdateDate>2025-01-10 11:51:31</sourceUpdateDate>
        <contentUpdateDate>2025-01-10 11:51:31</contentUpdateDate>
        <relations>
          <associations>
            <organization source="corda" type="isRegisteredBy">
              <availableLanguages>en</availableLanguages>
              <rcn>2384571</rcn>
              <id>934454545</id>
              <vatNumber>ESB66430653</vatNumber>
              <legalName>PEPTOMYC SL</legalName>
              <shortName>PEPTOMYC SL</shortName>
              <address>
                <street>CENTER CELLEX, CALLE NATZARET 115-117</street>
                <city>BARCELONA</city>
                <postalCode>08035</postalCode>
                <country>ES</country>
                <geolocation>41.370449300000004,2.1500219563810696</geolocation>
              </address>
              <relations>
                <categories>
                  <category classification="organizationActivityType" type="relatedOrganizationActivityType">
                    <language>en</language>
                    <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
                    <code>/PRC</code>
                    <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
                    <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
                  </category>
                </categories>
                <regions>
                  <region type="relatedNutsCode">
                    <name>Spain</name>
                    <rcn>242387496</rcn>
                    <nutsCode>ES</nutsCode>
                    <euCode>ES</euCode>
                    <isoCode>ES</isoCode>
                  </region>
                  <region type="relatedRegion">
                    <name>Spain</name>
                    <rcn>242387496</rcn>
                    <nutsCode>ES</nutsCode>
                    <euCode>ES</euCode>
                    <isoCode>ES</isoCode>
                  </region>
                </regions>
              </relations>
            </organization>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/ipr</code>
              <title>Intellectual Property Rights</title>
              <description>Result: Intellectual property rights linked to the results of EU funded research (FP7 onwards)</description>
              <displayCode>/Intellectual Property Rights</displayCode>
            </category>
            <category classification="iprType" type="isRegisteredAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/OTHER</code>
              <title>Other</title>
              <displayCode>/Other</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1318343</rcn>
        <id>101144681_E0540AFB3C76218E76013F1BFA33FAB1_IPRHORIZON</id>
        <title>Compound for the treatment of autoimmune diseases</title>
        <details>
          <iprAwarded></iprAwarded>
          <iprNumber>EP24382257.4</iprNumber>
          <iprDate>2024-03-11</iprDate>
          <iprPrefix>EP24382257.4</iprPrefix>
        </details>
        <sourceUpdateDate>2025-06-09 13:13:44</sourceUpdateDate>
        <contentUpdateDate>2025-06-09 13:13:44</contentUpdateDate>
        <relations>
          <associations>
            <organization source="corda" type="isRegisteredBy">
              <availableLanguages>en</availableLanguages>
              <rcn>2384571</rcn>
              <id>934454545</id>
              <vatNumber>ESB66430653</vatNumber>
              <legalName>PEPTOMYC SL</legalName>
              <shortName>PEPTOMYC SL</shortName>
              <address>
                <street>CENTER CELLEX, CALLE NATZARET 115-117</street>
                <city>BARCELONA</city>
                <postalCode>08035</postalCode>
                <country>ES</country>
                <geolocation>41.370449300000004,2.1500219563810696</geolocation>
              </address>
              <relations>
                <categories>
                  <category classification="organizationActivityType" type="relatedOrganizationActivityType">
                    <language>en</language>
                    <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
                    <code>/PRC</code>
                    <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
                    <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
                  </category>
                </categories>
                <regions>
                  <region type="relatedNutsCode">
                    <name>Spain</name>
                    <rcn>242387496</rcn>
                    <nutsCode>ES</nutsCode>
                    <euCode>ES</euCode>
                    <isoCode>ES</isoCode>
                  </region>
                  <region type="relatedRegion">
                    <name>Spain</name>
                    <rcn>242387496</rcn>
                    <nutsCode>ES</nutsCode>
                    <euCode>ES</euCode>
                    <isoCode>ES</isoCode>
                  </region>
                </regions>
              </relations>
            </organization>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/ipr</code>
              <title>Intellectual Property Rights</title>
              <description>Result: Intellectual property rights linked to the results of EU funded research (FP7 onwards)</description>
              <displayCode>/Intellectual Property Rights</displayCode>
            </category>
            <category classification="iprType" type="isRegisteredAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/OTHER</code>
              <title>Other</title>
              <displayCode>/Other</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode>/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="40">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-EIC-ACC-BF</code>
        <title>HORIZON EIC Accelerator Blended Finance</title>
        <description>HORIZON EIC Accelerator Blended Finance</description>
        <displayCode>/HORIZON EIC Accelerator Blended Finance</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>